197 related articles for article (PubMed ID: 25666484)
1. Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.
Iwase H
Int J Clin Oncol; 2015 Apr; 20(2):249-52. PubMed ID: 25666484
[No Abstract] [Full Text] [Related]
2. [Treatment guideline for breast cancer and SERM-treatment].
Iwase H; Yamamoto Y; Kawasoe T
Nihon Rinsho; 2007 Nov; 65 Suppl 9():636-40. PubMed ID: 18159717
[No Abstract] [Full Text] [Related]
3. Can quantifying hormone receptor levels guide the choice of adjuvant endocrine therapy for breast cancer?
Mackey JR
J Clin Oncol; 2011 Apr; 29(12):1504-6. PubMed ID: 21422423
[No Abstract] [Full Text] [Related]
4. Understanding the data, meeting patients' needs.
Kaufmann M
Breast; 2008 Apr; 17 Suppl 3():S1. PubMed ID: 18281217
[No Abstract] [Full Text] [Related]
5. Estrogen and progesterone receptors in breast cancer.
Ma CX
Clin Adv Hematol Oncol; 2011 May; 9(5):385-6. PubMed ID: 21685867
[No Abstract] [Full Text] [Related]
6. A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?
Hayes DF; Stearns V; Rae J; Flockhart D;
J Natl Cancer Inst; 2008 May; 100(9):610-3. PubMed ID: 18445818
[No Abstract] [Full Text] [Related]
7. Endocrine therapy in 2009: consideration of the tumor and the host.
Goetz MP; Ames MM; Weinshilboum M; Ingle JN
Oncology (Williston Park); 2009 Feb; 23(2):150-1, 154. PubMed ID: 19323295
[No Abstract] [Full Text] [Related]
8. The evolving use of SERDs in estrogen receptor-positive, HER2-negative metastatic breast cancer.
Jeselsohn RM
Clin Adv Hematol Oncol; 2021 Jul; 19(7):428-431. PubMed ID: 34236340
[No Abstract] [Full Text] [Related]
9. Hormonal therapy for advanced breast cancer.
Rugo HS
Hematol Oncol Clin North Am; 2007 Apr; 21(2):273-91. PubMed ID: 17512449
[TBL] [Abstract][Full Text] [Related]
10. A rose is no longer a rose.
Henderson IC
J Clin Oncol; 2002 Aug; 20(16):3365-8. PubMed ID: 12177095
[No Abstract] [Full Text] [Related]
11. Current status of hormone therapy in patients with hormone receptor positive (HR+) advanced breast cancer.
Dalmau E; Armengol-Alonso A; Muñoz M; Seguí-Palmer MÁ
Breast; 2014 Dec; 23(6):710-20. PubMed ID: 25311296
[TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy for breast cancer: an overview.
Cheung KL
Breast; 2007 Aug; 16(4):327-43. PubMed ID: 17499991
[TBL] [Abstract][Full Text] [Related]
13. Anti-hormones: mechanism and use in treatment of breast cancer.
Dinda S
Clin Lab Sci; 2012; 25(1):45-9. PubMed ID: 22458049
[TBL] [Abstract][Full Text] [Related]
14. A 62-year-old woman with a new diagnosis of breast cancer.
Come SE
JAMA; 2006 Mar; 295(12):1434-42. PubMed ID: 16551716
[No Abstract] [Full Text] [Related]
15. Clinical use of selective estrogen receptor modulators and down regulators with the main focus on breast cancer.
Baumann CK; Castiglione-Gertsch M
Minerva Ginecol; 2009 Dec; 61(6):517-39. PubMed ID: 19942839
[TBL] [Abstract][Full Text] [Related]
16. Revisiting the estrogen receptor pathway and its role in endocrine therapy for postmenopausal women with estrogen receptor-positive metastatic breast cancer.
Nagaraj G; Ma C
Breast Cancer Res Treat; 2015 Apr; 150(2):231-42. PubMed ID: 25762475
[TBL] [Abstract][Full Text] [Related]
17. [Adjuvant treatment of breast cancer. Endocrine therapy].
Mouridsen HT; Andersen J
Ugeskr Laeger; 2007 Sep; 169(37):3072-6. PubMed ID: 17877951
[TBL] [Abstract][Full Text] [Related]
18. [Breast neoplasms: predictive factors for endocrine therapy ].
Hayashi S
Nihon Rinsho; 2007 Jun; 65 Suppl 6():148-53. PubMed ID: 17682151
[No Abstract] [Full Text] [Related]
19. Advances in adjuvant hormonal therapy for postmenopausal women.
Strasser-Weippl K; Goss PE
J Clin Oncol; 2005 Mar; 23(8):1751-9. PubMed ID: 15755983
[No Abstract] [Full Text] [Related]
20. Predicting endocrine responsiveness: novel biomarkers on the horizon.
Kerstann KF; Bouzyk M; Abramovitz M; Leyland-Jones B
Oncology (Williston Park); 2009 Feb; 23(2):154, 156, 159. PubMed ID: 19323296
[No Abstract] [Full Text] [Related]
[Next] [New Search]
